
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Clin Respir J</journal-id><journal-id journal-id-type="iso-abbrev">Eur Clin Respir J</journal-id><journal-id journal-id-type="publisher-id">ECRJ</journal-id><journal-title-group><journal-title>European Clinical Respiratory Journal</journal-title></journal-title-group><issn pub-type="epub">2001-8525</issn><publisher><publisher-name>Co-Action Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26557245</article-id><article-id pub-id-type="pmc">4629770</article-id><article-id pub-id-type="publisher-id">24356</article-id><article-id pub-id-type="doi">10.3402/ecrj.v1.24356</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Defining severe asthma &#x02013; an approach to find new therapies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nanzer</surname><given-names>Alexandra M.</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Menzies-Gow</surname><given-names>Andrew</given-names></name></contrib></contrib-group><aff>Asthma and Allergy, Royal Brompton &#x00026; Harfield NHS Foundation Trust, London, United Kingdom</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Alexandra M. Nanzer, Respiratory Medicine, Royal Brompton &#x00026; Harfield NHS Foundation Trust, Sydney Street, London SW3 6NP, United Kingdom, Email: <email xlink:href="A.Nanzer-Kelly@rbht.nhs.uk">A.Nanzer-Kelly@rbht.nhs.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>6</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>1</volume><elocation-id content-type="doi">10.3402/ecrj.v1.24356</elocation-id><history><date date-type="received"><day>15</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Alexandra M. Nanzer and Andrew Menzies-Gow</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><p>Asthma is a chronic inflammatory disease that has reached epidemic proportions worldwide. It is treatable in the majority of patients, but there is no cure. Moreover, a proportion of patients suffer from severe, difficult-to-control disease with daily symptoms and high morbidity, making it imperative that we continue to improve our understanding of the underlying mechanisms of this disease. Severe asthma is a heterogeneous condition. A systematic approach to identify specific asthma phenotypes, including clinical characteristics and inflammatory processes, is the first step toward individualized, logical therapy. This review focuses on the need to characterize severe asthma phenotypes and on novel, targeted molecular treatment options currently under development.</p></abstract><kwd-group><kwd>severe asthma</kwd><kwd>comorbidities</kwd><kwd>phenotypes</kwd><kwd>new biological treatments</kwd></kwd-group></article-meta></front><body><p>Asthma is associated with significant morbidity and mortality and is one of the most common long-term conditions worldwide (<xref rid="CIT0001" ref-type="bibr">1</xref>). The prevalence of asthma has been rising over the past decade and currently affects up to 10% of the population in developed countries (<xref rid="CIT0002" ref-type="bibr">2</xref>, <xref rid="CIT0003" ref-type="bibr">3</xref>). Fortunately, a majority of patients achieve control if they take their medication regularly and as prescribed, and international guidelines assist the treating physician to implement a stepwise escalation of treatment until symptoms are controlled (<xref rid="CIT0002" ref-type="bibr">2</xref>). However, a substantial number of patients fail to gain clinical benefit from any of the standard treatments. Poor compliance may be a reason for this. However, it is noteworthy that studies assessing asthma control observed persistent symptoms in over 20% of patients despite treatment adherence in exceptional trial circumstances and in selected patient groups (<xref rid="CIT0003" ref-type="bibr">3</xref>). It is therefore widely acknowledged that a small proportion of patients have a genuine poor response, in particular to corticosteroids. These patients have a greater risk of dying of their disease and their lives are often blighted by their condition, notwithstanding the disproportional amount of healthcare resources spent.</p><p>A well-defined, unbiased approach that defines the clinical characteristics that specify distinct phenotypes of asthma is critical for a better understanding of disease pathogenesis and thus successful management.</p><p>It is essential to differentiate severe asthma from difficult-to-control asthma. Assessment of each and every patient presenting with recurrent episodes of wheezing, chest tightness, and/or cough requires a careful history focusing on symptoms, exacerbating triggers and occupational as well as environmental factors. With the correct diagnosis established, systematic evaluation has the potential to identify up to half of previously deemed severe asthmatics as difficult-to-treat asthmatics (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0005" ref-type="bibr">5</xref>). Patients can be labeled as suffering from severe asthma with ongoing symptoms after an alternative diagnosis has been excluded, comorbidities have been treated, allergen exposures are being avoided and, last but not least, adherence with treatment and inhaler technique has been checked (<xref ref-type="fig" rid="F0001">Fig. 1</xref>).</p><fig id="F0001" position="float"><label>Fig. 1</label><caption><p>Investigation and treatment of severe asthma.</p><p>A stepwise approach toward individualized asthma treatment incorporates a systematic assessment with a critical review of diagnosis, comorbidities and compliance.</p></caption><graphic xlink:href="ECRJ-1-24356-g001"/></fig><p>In 2013, the international European Respiratory Society&#x02013;American Thoracic Society guidelines classified severe asthma as a disease that requires treatment with high-dose inhaled corticosteroids and/or systemic corticosteroids to prevent it from becoming uncontrolled or that remains uncontrolled despite this therapy (<xref rid="CIT0006" ref-type="bibr">6</xref>). Any of the following criteria qualifies a patient as having ongoing symptoms and therefore severe asthma:<list list-type="order"><list-item><p>Consistently poor symptom control: Asthma Control Questionnaire (ACQ) score is consistently &#x0003e;1.5 or Asthma Control Test (ACT) score is &#x0003c;20.</p></list-item><list-item><p>Frequent severe exacerbations requiring at least courses of oral corticosteroids for a minimum of 3 days in the previous year.</p></list-item><list-item><p>One or more hospitalization, intensive care unit admission, or invasive ventilation in the previous year.</p></list-item><list-item><p>Forced expiratory volume (FEV<sub>1</sub>)&#x0003c;80% predicted (with FEV<sub>1</sub>/FVC (forced vital capacity) reduced to less than the lower limit of normal).</p></list-item></list>
</p><sec id="S0002"><title>Comorbidities</title><p>Atopic rhinosinusitis, gastroesophageal reflux disease (GERD), sleep apnea, and obesity are well-known comorbidities that can aggravate and perpetuate and/or masquerade as asthma. Epidemiological studies report less atopy by skin test in severe asthma, but a high prevalence of chronic rhinosinusitis and nasal polyposis (<xref rid="CIT0007" ref-type="bibr">7</xref>, <xref rid="CIT0008" ref-type="bibr">8</xref>). Severe asthma is disproportionally high in aspirin-exacerbated respiratory disease (AERD), where the majority of patients suffer from nasal polyposis (<xref rid="CIT0009" ref-type="bibr">9</xref>).</p><p>Symptoms of GERD include cough and chest tightness. Heartburn and indigestion contribute to night awakenings and may mimic asthma. Prevalence of GERD in asthma is variable and can range from 12 to 85% (<xref rid="CIT0010" ref-type="bibr">10</xref>). Treatment has proven beneficial for asthma-related quality of life. It was shown to reduce nocturnal symptoms and exacerbation frequency, and some studies report reduction in the use of short-acting beta<sub>2</sub> agonists (<xref rid="CIT0011" ref-type="bibr">11</xref>). Notwithstanding this, bronchodilators can potentially aggravate GERD by reducing esophageal sphincter tone (<xref rid="CIT0012" ref-type="bibr">12</xref>).</p><p>Obesity is a major risk factor for asthma, and the epidemic increase in obesity is likely to be a significant contributor to the increase in numbers of patients with severe asthma. Factors such as insulin resistance, altered adaptive and innate immunity, changes in mechanical loading of the chest wall and abdomen, and increased airway hyperresponsiveness secondary to low-lung-volume breathing have all been linked to obesity-related asthma (<xref rid="CIT0013" ref-type="bibr">13</xref>). Weight loss has been shown to improve asthma control, and a recent paper reported reversal of a proinflammatory cytokine milieu after bariatric surgery (<xref rid="CIT0014" ref-type="bibr">14</xref>, <xref rid="CIT0015" ref-type="bibr">15</xref>). Treatment of obesity-related asthma with corticosteroids often proves disappointing. The pivotal role of adipose tissue resident immune cells (i.e. macrophages and mast cells as well as proinflammatory adipocytokines) makes them targets for novel biological treatments such as peroxisome proliferator activated receptor (PPAR) agonists and, in particular, in association with sputum eosinophilia, anti-interleukin (IL)-5 (<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0017" ref-type="bibr">17</xref>).</p><p>Severe asthma is frequently associated with fungal and/or mold sensitivity. Patients with persistently uncontrolled asthma are often chronically colonized with <italic>Aspergillus</italic>, <italic>Candida</italic>, <italic>Penicillium</italic>, and <italic>Curvularia</italic> species (<xref rid="CIT0018" ref-type="bibr">18</xref>&#x02013;<xref rid="CIT0020" ref-type="bibr">20</xref>). All patients should undergo both skin prick testing (SPT) and specific serum IgE tests: SPT has a sensitivity of around 50&#x02013;60%, less than half of patients have a positive reaction to both tests and there is generally insufficient concordance between the two tests (<xref rid="CIT0021" ref-type="bibr">21</xref>&#x02013;<xref rid="CIT0023" ref-type="bibr">23</xref>).</p><p>The first case reports linking asthma and obstructive sleep apnea (OSA) emerged in the late 1970s (<xref rid="CIT0024" ref-type="bibr">24</xref>). Snoring, observed apnea, and poorly controlled asthma are closely linked, and patients who have OSA and nocturnal asthma may have similar clinical presentations (<xref rid="CIT0025" ref-type="bibr">25</xref>&#x02013;<xref rid="CIT0028" ref-type="bibr">28</xref>). Treatment with continuous positive airway pressure (CPAP) significantly improves asthma quality of life, lung function, and short-term beta<sub>2</sub> agonist requirements (<xref rid="CIT0029" ref-type="bibr">29</xref>, <xref rid="CIT0030" ref-type="bibr">30</xref>).</p><p>Anxiety and depression are subjective emotions that may escape the attention of clinicians <italic>and</italic> patients with chronic diseases. Patients with severe asthma are under protracted distress and are at increased risk of developing psychiatric disorders, most commonly panic disorder, depression, and anxiety (<xref rid="CIT0031" ref-type="bibr">31</xref>, <xref rid="CIT0032" ref-type="bibr">32</xref>). Moreover, studies have shown decreased asthma control with higher exacerbation rates in patients suffering from anxiety with or without depression (<xref rid="CIT0033" ref-type="bibr">33</xref>, <xref rid="CIT0034" ref-type="bibr">34</xref>). The challenges of understanding and responding appropriately to the emotional factors of the chronic disease that asthma is mustn't be neglected, and patients might benefit from formal psychological support services.</p><p>Smoking is as common in asthmatics as it is in the general population (<xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>). Smoking asthmatics have a more rapid decline in lung function, more symptoms and exacerbations than nonsmokers and an impaired steroid response (<xref rid="CIT0037" ref-type="bibr">37</xref>). Their inflammatory profile in blood and sputum differs compared to that of nonsmoking asthmatics (<xref rid="CIT0038" ref-type="bibr">38</xref>). All patients should be offered smoking cessation advice (<xref rid="CIT0038" ref-type="bibr">38</xref>&#x02013;<xref rid="CIT0040" ref-type="bibr">40</xref>).</p></sec><sec id="S0003"><title>Asthma phenotyping</title><p>Recently, a significant effort has been directed at defining severe asthma and in particular its subgroups or phenotypes. Asthma is a heterogeneous disease, and phenotype-specific therapies promise enhanced treatment success. A phenotype is defined as the apparent characteristics of an organism resulting from its interactions with the environment and its genetic makeup (<xref rid="CIT0041" ref-type="bibr">41</xref>).</p><p>Historically, asthma has been termed a T-helper cell type 2 (Th2)-driven disease characterized by reversible airway obstruction, thickened airway smooth muscle cells, subepithelial fibrosis, and a characteristic aberrant immune regulation with a predominance of Th2 cells secreting cytokines IL-4, IL-5, and IL-13 (<xref rid="CIT0042" ref-type="bibr">42</xref>). IL-4 is a key element in driving differentiation from na&#x000ef;ve Th0 cells to Th2 cells, and it promotes B cell class switching to IgE production, mast cell growth, and eosinophil recruitment (<xref rid="CIT0043" ref-type="bibr">43</xref>). IL-5 is responsible for driving eosinophil differentiation, survival and tissue cytotoxicity (<xref rid="CIT0044" ref-type="bibr">44</xref>), and IL-13 mediates airway hyperactivity and increased mucus production and also promotes B cell IgE production. Other cells known to be central to allergic inflammation are mast cells, eosinophils, neutrophils, macrophages, dendritic cells and, in recent years, invariant natural killer T cells, innate lymphoid cells, and Th17 cells (<xref ref-type="fig" rid="F0002">Fig. 2</xref>).</p><fig id="F0002" position="float"><label>Fig. 2</label><caption><p>Immunopathology in asthma.</p><p>Allergens are presented to na&#x000ef;ve T-helper cells (Th0) via antigen presenting cells (APCs), resulting in the differentiation into Th1, Th17 and Th2 cells and the release of cell-specific cytokines. Th2 cytokines mediate airway eosinophil and mast cell recruitment, B-cell IgE isotype class switching, and mucus secretion. Allergen specific B-cells switch from IgM-producing to IgE-producing cells. Interleukin-17, which is produced by Th17 cells, mediates airway neutrophilia by inducing the production of CXC chemokine. IL=interleukin, TCR=T-cell receptor, IFN-&#x003b3;=interferon gamma, TNF=tumor necrosis factor, Fc&#x0025b;R=high-affinity IgE receptor.</p></caption><graphic xlink:href="ECRJ-1-24356-g002"/></fig><p>Several approaches have been taken to characterize asthma subgroups. The Severe Asthma Research Program (SARP) identified five asthma subphenotypes by unbiased cluster analysis, three of which are severe asthma (<xref rid="CIT0045" ref-type="bibr">45</xref>): the early-onset allergic type and the late-onset eosinophilic phenotype are both orchestrated by Th2 cells. They are clinically distinct yet overlap immunologically. A Th2-cell signature is further believed to play a predominant role in exercise-induced asthma (EIA), with mast cells and their mediators understood to be driving inflammation in EIA (<xref rid="CIT0046" ref-type="bibr">46</xref>) and AERD. A lack of Th2 biomarkers is seen in obesity-related asthma and neutrophilic asthma (see <xref ref-type="table" rid="T0001">Table 1</xref>).</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Asthma phenotypes according to their cytokine profiles divided into Th2-high and Th2-low asthma (<xref rid="CIT0041" ref-type="bibr">41</xref>)
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">T cell signature</th><th align="center" rowspan="1" colspan="1">Phenotype</th><th align="center" rowspan="1" colspan="1">Biomarkers</th><th align="center" rowspan="1" colspan="1">Therapy</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Th2-high</td><td align="left" rowspan="1" colspan="1">Early-onset allergic</td><td align="left" rowspan="1" colspan="1">Specific IgE, +SPT</td><td align="left" rowspan="1" colspan="1">Corticosteroids, anti-IgE</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Late-onset eosinophilic</td><td align="left" rowspan="1" colspan="1">Sputum eosinophilia, IL-5</td><td align="left" rowspan="1" colspan="1">Poor response to corticosteroids, anti-IL-5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Exercise induced</td><td align="left" rowspan="1" colspan="1">Mast cells</td><td align="left" rowspan="1" colspan="1">Leukotriene receptor antagonists, SABA</td></tr><tr><td align="left" rowspan="1" colspan="1">Th2-low</td><td align="left" rowspan="1" colspan="1">Obesity related</td><td align="left" rowspan="1" colspan="1">Mast cells, adiponectin, Th1 cytokines</td><td align="left" rowspan="1" colspan="1">Poor response to corticosteroids<break/>Weight loss, PPAR agonists</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Neutrophilic</td><td align="left" rowspan="1" colspan="1">Th17, sputum neutrophilia</td><td align="left" rowspan="1" colspan="1">Vitamin D, p38 MAPK inhibitors, Macrolides. Poor response to corticosteroids</td></tr></tbody></table></table-wrap><p>In another study using cluster analysis, sputum eosinophilia was incorporated. Consequent upon this, a phenotype of early-onset severe atopic asthma, late-onset asthma with persistent eosinophilia, and a cluster of obese females with late-onset asthma without eosinophilia were identified (<xref rid="CIT0047" ref-type="bibr">47</xref>).</p><p>Molecular phenotyping has led to the development of biomarkers that specifically target Th2 responses in the lung: Woodruff and colleagues identified periostin (<italic>POSTN</italic>), chloride channel regulator 1 (<italic>CLCA1</italic>), and serpin peptidase inhibitor, clade B, member 2 (<italic>SERPINB2</italic>) as epithelial genes that were specifically induced in asthma and directly regulated by IL-13 <italic>in vitro</italic> (<xref rid="CIT0048" ref-type="bibr">48</xref>). They further identified patients with distinctly higher levels of IL-5 and IL-13, termed Th2-high asthma. This was in contrast with patients with cytokine expression similar to that of healthy controls, including Th1 cytokines IL-12 and interferon gamma (IFN&#x003b3;), which were significantly lower in the Th2-high group. The Th2-high and Th2-low groups also differed clinically, with the Th2-high group showing significant higher atopy and higher eosinophil levels in peripheral blood and bronchoalveolar lavage (BAL). Of particular interest was their observation of corticosteroid responsiveness: lung function of Th2-low asthmatics failed to improve following treatment with inhaled corticosteroids; in fact, patients&#x02019; FEV<sub>1</sub> deteriorated in the first month, suggesting a detrimental effect of corticosteroids in Th2-low asthma (<xref rid="CIT0048" ref-type="bibr">48</xref>).</p></sec><sec id="S0004"><title>Novel therapies &#x02013; targeting the right patient: Th2-high asthma</title><p>Omalizumab remains so far the most successfully applied monoclonal antibody to treat allergic Th2-high asthma by reducing the exacerbation rate. Omalizumab is a humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE), but not to IgE that is already bound by the high-affinity IgE receptor (Fc&#x0025b;RI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. Steric hindrance by the receptor means the receptor is not accessible to omalizumab binding, thus averting anaphylaxis. In a number of studies conducted so far, patients treated with omalizumab reported significant improvements in asthma-related symptoms, allowing for a reduction in corticosteroid and rescue inhaler use (<xref rid="CIT0049" ref-type="bibr">49</xref>&#x02013;<xref rid="CIT0051" ref-type="bibr">51</xref>). It appears that patients with blood eosinophilia, high levels of exhaled nitric oxide, and serum periostin most benefit from anti-IgE treatment (<xref rid="CIT0052" ref-type="bibr">52</xref>). However, evidence is now emerging that omalizumab has a role in non-atopic asthma. A recent trial demonstrated significantly increased asthma control in 29 non-atopic patients and a trend to reduced exacerbation rates and improved lung function (<xref rid="CIT0053" ref-type="bibr">53</xref>, <xref rid="CIT0054" ref-type="bibr">54</xref>). A small randomized controlled trial comparing treatment with omalizumab and placebo in non-atopic asthmatics over a period of 16 weeks found a trend toward a decrease in exacerbations and a significant improvement in lung function in omalizumab-treated patients, as compared with the placebo group. In addition, the authors showed that the expression of the high-affinity IgE receptor on blood plasmacytoid dendritic cells decreased significantly in the active group but not in the placebo group (<xref rid="CIT0054" ref-type="bibr">54</xref>). Larger trials, and in particular trials shedding light on how best to identify non-atopic patients who are likely going to respond to anti-IgE treatment, are needed.</p><p>The success of anti-IgE therapy is limited by the fact that IgE production is not affected. Treatment has to be given regularly and on a long-term basis. Brightbill et al. have successfully created a monoclonal antibody against the M1&#x02032; segment of membrane IgE on human IgE-switched B cells, resulting in depletion of IgE-switched B cells via apoptosis or/and antibody-dependent cell-mediated cytotoxicity (<xref rid="CIT0055" ref-type="bibr">55</xref>). Total IgE levels were reduced without other immunoglobulin isotypes being affected. A phase IIb randomized controlled trial is currently testing its efficacy in uncontrolled allergic asthma, and study results are expected in 2015 (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrial.gov/ct2/show/NCT01582503">http://clinicaltrial.gov/ct2/show/NCT01582503</ext-link>).</p><p>Promising newer treatments targeting the Th2 pathway with steroid-sparing potential include the anti-IL-5 antibody mepolizumab. The first randomized controlled trials with anti-IL-5 were conducted in patients with mild to moderate asthma (<xref rid="CIT0056" ref-type="bibr">56</xref>, <xref rid="CIT0057" ref-type="bibr">57</xref>). These studies failed to show a beneficial effect on lung function. However, after targeting patients with severe asthma and refractory airway eosinophilia and choosing the correct primary outcome (i.e. asthma exacerbations), anti-IL-5 treatment has been shown to significantly reduce exacerbations and oral corticosteroid doses required to control symptoms, and it has been well tolerated during the study period of over a year (<xref rid="CIT0058" ref-type="bibr">58</xref>). Benralizumab, an IL-5 receptor alpha subunit (IL-5R&#x003b1;) antibody, not only reduced peripheral blood eosinophils but significantly reduced eosinophil counts in airway mucosa and submucosa (<xref rid="CIT0059" ref-type="bibr">59</xref>). However, neither of the two treatments has had any effect on lung function or patient-rated asthma control.</p><p>Clinical trials have also investigated targeted therapies against the Th2 cytokines IL-4 and IL-13. Pitrakinra is an IL-4 mutein, which binds to the IL-4R&#x003b1; subunit and prevents the inflammation induced by IL-4 and IL-13. It has been shown to reduce allergen-induced airway responses when given in inhaled or subcutaneous form in a study of mild asthmatics and to reduce exacerbation rates in those with eosinophilia (<xref rid="CIT0060" ref-type="bibr">60</xref>, <xref rid="CIT0061" ref-type="bibr">61</xref>). In moderate to severe asthma, the fully human monoclonal IL-4R-&#x003b1; dupilumab improved lung function, symptoms and exacerbation rate (<xref rid="CIT0062" ref-type="bibr">62</xref>).</p><p>Periostin has proven to be a prognostic biomarker for treatment with the anti-IL-13 antibody Lebrikizumab. A recent study demonstrated that treatment with Lebrikizumab increased FEV<sub>1</sub> in patients with a high serum periostin level (<xref rid="CIT0063" ref-type="bibr">63</xref>). To date, the most successful anti-Th2 cytokine therapies have focused on accurate identification of a patient's phenotype to allow for personalized treatment regimes.</p></sec><sec id="S0005"><title>Non-Th2-high asthma: a different challenge</title><p>Treatments targeting other possible inflammatory mediators have shown less clear evidence of clinical benefit, and the reason for this might stem from the difficulty of a clear definition: Th2-low asthma remains identified by the absence of Th2 biomarkers. Although the presence of a neutrophilic phenotype of asthma has been suggested, its use as a biomarker is imperfect. In contrast to the significant association between blood eosinophilia and airway eosinophilia in patients with asthma (who are not treated with systemic corticosteroids), there is no correlation at all between blood neutrophilia and airway neutrophilia (<xref rid="CIT0064" ref-type="bibr">64</xref>). Furthermore, there is no consent as to the level of airway neutrophilia that would define pathology; neutrophils, unlike eosinophils, are a normal component of the cells retrieved in induced sputum. There are robust data, however, that the later onset, obese, non-eosinophilic phenotype is often particularly steroid insensitive and difficult to control. Interestingly, patients with severe asthma are found to have higher levels of the pro-inflammatory cytokine IL-17A in sputum and BAL, and the severity of airway hypersensitivity correlates with airway neutrophilia and levels of IL-17A expression (<xref rid="CIT0065" ref-type="bibr">65</xref>&#x02013;<xref rid="CIT0067" ref-type="bibr">67</xref>). Studies in mice and humans suggest an association between steroid resistance and Th17-mediated disease: adoptive transfer of Th17 cells resulted in increased levels of CXC chemokines and G-CSF in the BAL fluid of SCID mice, and treatment with dexamethasone resulted in increased neutrophil numbers but no improvement of airway hyperresponsiveness (<xref rid="CIT0068" ref-type="bibr">68</xref>). Glucocorticoid resistance is associated with an increased expression of the transcriptionally inactive glucocorticoid receptor beta (GR-&#x003b2;) (<xref rid="CIT0069" ref-type="bibr">69</xref>&#x02013;<xref rid="CIT0071" ref-type="bibr">71</xref>). Furthermore, GR-&#x003b2; increases in response to exogenous IL-17A and IL-17F, an effect that was more prominent in asthmatics than in healthy controls (<xref rid="CIT0072" ref-type="bibr">72</xref>). Further accounting for corticosteroid insensitivity are defects in glucocorticoid receptor binding and activation of transcription factors such as AP1, which is activated by pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF&#x003b1;) or through failure to induce regulatory cytokines like IL-10 (<xref rid="CIT0073" ref-type="bibr">73</xref>).</p><p>Anti-TNF&#x003b1; treatment was tested in severe (etanercept) (<xref rid="CIT0074" ref-type="bibr">74</xref>, <xref rid="CIT0075" ref-type="bibr">75</xref>) and moderate (infliximab) (<xref rid="CIT0076" ref-type="bibr">76</xref>) asthmatics and resulted in improved asthma control, FEV<sub>1</sub>, and bronchial hyperreactivity. However, the effect ceased as soon as the drug was discontinued. The fully human anti-TNF antibody golimumab did not have any clinical benefit, but resulted in an increase of respiratory infections and malignancies leading to an early discontinuation of the trial (<xref rid="CIT0077" ref-type="bibr">77</xref>).</p><p>In a randomized controlled trial, the human anti-IL-17 receptor monoclonal antibody brodalumab was not superior to placebo in terms of asthma control (<xref rid="CIT0078" ref-type="bibr">78</xref>). Interestingly, the authors observed a nominal significance in a subgroup of patients with high bronchodilator reversibility. Further studies of brodalumab in this asthma subpopulation are warranted. Anti-IL-9 (<xref rid="CIT0079" ref-type="bibr">79</xref>), agents targeting TSLP (<xref rid="CIT0080" ref-type="bibr">80</xref>), chemokine inhibitors (CCR3 and CCR4) (<xref rid="CIT0081" ref-type="bibr">81</xref>), phosphodiesterase and kinase inhibitors (<xref rid="CIT0082" ref-type="bibr">82</xref>) and the use of vaccination (<xref rid="CIT0083" ref-type="bibr">83</xref>) with the aim to shift from Th2 to Th1 are all under development, but have yet to show any clear clinical benefit.</p><p>Deficiency in serum vitamin D has been linked to predisposing individuals to chronic inflammatory lung disease, such as asthma and viral respiratory infections, with higher rates of hospital admission for respiratory diseases (<xref rid="CIT0084" ref-type="bibr">84</xref>&#x02013;<xref rid="CIT0086" ref-type="bibr">86</xref>). Reports have shown a positive correlation between vitamin D deficiency and asthma prevalence (<xref rid="CIT0087" ref-type="bibr">87</xref>&#x02013;<xref rid="CIT0089" ref-type="bibr">89</xref>). Manipulation of vitamin D status for therapeutic benefit in asthma is currently highly topical, with studies suggestive of a role in steroid-refractory asthma (<xref rid="CIT0090" ref-type="bibr">90</xref>, <xref rid="CIT0091" ref-type="bibr">91</xref>).</p><p>Macrolide antibiotics have anti-inflammatory and immune-modulatory effects. They also increase gastrointestinal motility and to that extent might prove beneficial in patients with significant GERD. They have been proven effective in chronic respiratory diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). They have been shown to reduce severe exacerbations in patients with non-eosinophilic asthma and to have significantly improved the Asthma Quality of Life Questionnaire score (<xref rid="CIT0092" ref-type="bibr">92</xref>). However, chronic antimicrobial use is associated with the risks of population resistance, and treatment should be restricted to severe asthma patients at greatest unmet need despite optimal asthma management.</p><p>Methotrexate has proven a valid agent in patients who, despite long-term treatment with oral glucocorticosteroids, fail to gain satisfactory control of their asthma (<xref rid="CIT0093" ref-type="bibr">93</xref>). Due to considerable side effects, close monitoring is needed and treatment should only be initiated in specialist centers.</p></sec><sec id="S0006"><title>Bronchial thermoplasty</title><p>Smooth muscle hyperplasia is a distinctive feature of asthma. Applying radiofrequency energy to subsegmental airways has been shown to reduce muscle mass at the site of thermoplasty. Trials demonstrated a reduction in the number of severe asthma exacerbations and an improvement in asthma-specific quality of life (<xref rid="CIT0094" ref-type="bibr">94</xref>), and a recent study found no adverse events after a 5-year follow-up period (<xref rid="CIT0095" ref-type="bibr">95</xref>). Although guidelines recommend bronchial thermoplasty for adults with severe asthma that is not controlled with inhaled corticosteroids and long-acting beta<sub>2</sub> agonists (LABAs), it is currently unclear which phenotypes respond best to the treatment. Studies are needed to identify the phenotype of patients who will derive significant clinical benefit most from this invasive procedure.</p></sec><sec sec-type="conclusion" id="S0007"><title>Conclusion</title><p>Asthma is common, and in most cases it is a treatable disease. However, patients with difficult-to-treat asthma remain a challenge for every healthcare professional, and there is a significant unmet clinical need. It has become abundantly clear that asthma is a heterogeneous disease in its course and variation in response to treatment. A systematic approach to the complexity and diversity of asthma pathophysiology is essential. Up until recently, trials testing anti-inflammatory therapy based on targeting cytokines have, despite highly promising results in animal models, proven to be disappointing. However, in carefully selected patients, when asthma phenotypes are taken into account, novel biological treatments may lead to significant advances. Discriminatory biomarkers and genetic profiling may aid identification in support of personalized pharmacotherapy. Within the next 5 to 10 years, logical, targeted therapies will be available for patients with Th2-high severe asthma, and our understanding of the mechanisms driving Th2-low asthma will be significantly advanced.</p></sec></body><back><sec id="S0008"><title>Conflict of interest and funding</title><p>Dr Nanzer has no competing financial interests. Dr Menzies-Gow has attended advisory boards for Roche, Mundi Pharma, Boeringher Ingelheim, Amgen, and Johnson &#x00026; Johnson. He has received lecture fees from Novartis, NAPP, and Glaxo SmithKline. He has attended international conferences with Novartis and Boeringher Ingelheim.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FD</given-names></name><name><surname>Vercelli</surname><given-names>D</given-names></name></person-group><article-title>Asthma</article-title><source>Lancet</source><year>2013</year><volume>382</volume><fpage>1360</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24041942</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="book"><collab>BTS/SIGN</collab><article-title>British guideline on the management of asthma</article-title><source>A national clinical guideline</source><year>2008</year><publisher-name>British Thoracic Society and Scottish Intercollegiate Guidelines Network (SIGN)</publisher-name><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.sign.ac.uk/guidelines/fulltext/101/index.html">http://www.sign.ac.uk/guidelines/fulltext/101/index.html</ext-link> (Revised January 2012)</comment></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Boushey</surname><given-names>HA</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Clark</surname><given-names>TJ</given-names></name><name><surname>Pauwels</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>170</volume><fpage>836</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">15256389</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>DS</given-names></name><name><surname>Campbell</surname><given-names>DA</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Pfeffer</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name></person-group><article-title>Systematic assessment of difficult-to-treat asthma</article-title><source>Eur Respir J</source><year>2003</year><volume>22</volume><fpage>478</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">14516138</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaney</surname><given-names>LG</given-names></name><name><surname>Conway</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Johnston</surname><given-names>BT</given-names></name><name><surname>English</surname><given-names>C</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>561</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12832665</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Wenzel</surname><given-names>SE</given-names></name><name><surname>Brozek</surname><given-names>JL</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma</article-title><source>Eur Respir J</source><year>2014</year><volume>43</volume><fpage>343</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">24337046</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>WC</given-names></name></person-group><article-title>Update in asthma 2007</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>177</volume><fpage>1068</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">18460462</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Hung</surname><given-names>SH</given-names></name></person-group><article-title>Comorbidity profile of chronic rhinosinusitis: a population-based study</article-title><source>The Laryngoscope</source><year>2014</year><pub-id pub-id-type="doi">10.1002/lary.24581</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>MA</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name></person-group><article-title>An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2014</year><volume>14</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24300420</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>SM</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Blumin</surname><given-names>JH</given-names></name><name><surname>Warner</surname><given-names>EA</given-names></name><name><surname>Pellegrini</surname><given-names>CA</given-names></name><name><surname>Chan</surname><given-names>WW</given-names></name></person-group><article-title>Respiratory manifestations of gastroesophageal reflux disease</article-title><source>Ann N Y Acad Sci</source><year>2013</year><volume>1300</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">24117633</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiljander</surname><given-names>TO</given-names></name><name><surname>Salomaa</surname><given-names>ER</given-names></name><name><surname>Hietanen</surname><given-names>EK</given-names></name><name><surname>Terho</surname><given-names>EO</given-names></name></person-group><article-title>Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole</article-title><source>Chest</source><year>1999</year><volume>116</volume><fpage>1257</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10559084</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledford</surname><given-names>DK</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name></person-group><article-title>Asthma and comorbidities</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2013</year><volume>13</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">23222157</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sideleva</surname><given-names>O</given-names></name><name><surname>Dixon</surname><given-names>A</given-names></name></person-group><article-title>The many faces of asthma in obesity</article-title><source>J Cell Biochem</source><year>2014</year><volume>115</volume><fpage>421</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/jcb.24678</pub-id><pub-id pub-id-type="pmid">24115053</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>PG</given-names></name></person-group><article-title>Obesity and asthma</article-title><source>Ann Am Thorac Soc</source><year>2013</year><volume>10</volume><fpage>S138</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">24313764</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toh</surname><given-names>JJ</given-names></name><name><surname>Pasupathy</surname><given-names>S</given-names></name><name><surname>Poopalalingam</surname><given-names>RA</given-names></name><name><surname>Koh</surname><given-names>MS</given-names></name></person-group><article-title>Can bariatric surgery be performed safely in patients with severe treatment-resistant asthma?</article-title><source>Obes Surg</source><year>2014</year><volume>24</volume><fpage>334</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24272887</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Periyalil</surname><given-names>HA</given-names></name><name><surname>Gibson</surname><given-names>PG</given-names></name><name><surname>Wood</surname><given-names>LG</given-names></name></person-group><article-title>Immunometabolism in obese asthmatics: are we there yet?</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><fpage>3506</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">24025484</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>D</given-names></name><name><surname>Newby</surname><given-names>C</given-names></name><name><surname>Symon</surname><given-names>FA</given-names></name><name><surname>Haldar</surname><given-names>P</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><etal/></person-group><article-title>Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>188</volume><fpage>657</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">23590263</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denning</surname><given-names>DW</given-names></name><name><surname>O'Driscoll</surname><given-names>BR</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name><name><surname>Bowyer</surname><given-names>P</given-names></name><name><surname>Niven</surname><given-names>RM</given-names></name></person-group><article-title>The link between fungi and severe asthma: a summary of the evidence</article-title><source>Eur Respir J</source><year>2006</year><volume>27</volume><fpage>615</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">16507864</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salo</surname><given-names>PM</given-names></name><name><surname>Arbes</surname><given-names>SJ</given-names><suffix>Jr</suffix></name><name><surname>Sever</surname><given-names>M</given-names></name><name><surname>Jaramillo</surname><given-names>R</given-names></name><name><surname>Cohn</surname><given-names>RD</given-names></name><name><surname>London</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Exposure to <italic>Alternaria alternata</italic> in US homes is associated with asthma symptoms</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>118</volume><fpage>892</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17030243</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>RK</given-names></name><name><surname>Prochnau</surname><given-names>JJ</given-names></name></person-group><article-title>Alternaria-induced asthma</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>113</volume><fpage>227</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">14767434</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>WL</given-names></name><name><surname>Letz</surname><given-names>KL</given-names></name><name><surname>Evans</surname><given-names>TS</given-names></name><name><surname>Giese</surname><given-names>JK</given-names></name></person-group><article-title>Evaluating the response of patients undergoing both allergy skin testing and in vitro allergy testing with the ImmunoCAP Technology System</article-title><source>J Am Acad Nurse Pract</source><year>2003</year><volume>15</volume><fpage>415</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">14560438</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>PJ</given-names></name><name><surname>Hooper</surname><given-names>R</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Jarvis</surname><given-names>D</given-names></name><name><surname>Burney</surname><given-names>P</given-names></name></person-group><article-title>Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I</article-title><source>Clin Exp Allergy</source><year>2007</year><volume>37</volume><fpage>780</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17456226</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Driscoll</surname><given-names>BR</given-names></name><name><surname>Powell</surname><given-names>G</given-names></name><name><surname>Chew</surname><given-names>F</given-names></name><name><surname>Niven</surname><given-names>RM</given-names></name><name><surname>Miles</surname><given-names>JF</given-names></name><name><surname>Vyas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma</article-title><source>Clin Exp Allergy</source><year>2009</year><volume>39</volume><fpage>1677</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19689458</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudgel</surname><given-names>DW</given-names></name><name><surname>Shucard</surname><given-names>DW</given-names></name></person-group><article-title>Coexistence of sleep apnea and asthma resulting in severe sleep hypoxemia</article-title><source>JAMA</source><year>1979</year><volume>242</volume><fpage>2789</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">501891</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekici</surname><given-names>A</given-names></name><name><surname>Ekici</surname><given-names>M</given-names></name><name><surname>Kurtipek</surname><given-names>E</given-names></name><name><surname>Keles</surname><given-names>H</given-names></name><name><surname>Kara</surname><given-names>T</given-names></name><name><surname>Tunckol</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of asthma-related symptoms with snoring and apnea and effect on health-related quality of life</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>3358</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16304284</pub-id></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>LG</given-names></name><name><surname>Lindberg</surname><given-names>A</given-names></name><name><surname>Franklin</surname><given-names>KA</given-names></name><name><surname>Lundback</surname><given-names>B</given-names></name></person-group><article-title>Symptoms related to obstructive sleep apnoea are common in subjects with asthma, chronic bronchitis and rhinitis in a general population</article-title><source>Respir Med</source><year>2001</year><volume>95</volume><fpage>423</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11392586</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yigla</surname><given-names>M</given-names></name><name><surname>Tov</surname><given-names>N</given-names></name><name><surname>Solomonov</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>AH</given-names></name><name><surname>Harlev</surname><given-names>D</given-names></name></person-group><article-title>Difficult-to-control asthma and obstructive sleep apnea</article-title><source>J Asthma</source><year>2003</year><volume>40</volume><fpage>865</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">14736085</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julien</surname><given-names>JY</given-names></name><name><surname>Martin</surname><given-names>JG</given-names></name><name><surname>Ernst</surname><given-names>P</given-names></name><name><surname>Olivenstein</surname><given-names>R</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Lemiere</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma</article-title><source>J Allergy Clin Immunol</source><year>2009</year><volume>124</volume><fpage>371</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19560194</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhalil</surname><given-names>M</given-names></name><name><surname>Schulman</surname><given-names>ES</given-names></name><name><surname>Getsy</surname><given-names>J</given-names></name></person-group><article-title>Obstructive sleep apnea syndrome and asthma: the role of continuous positive airway pressure treatment</article-title><source>Ann Allergy Asthma Immunol</source><year>2008</year><volume>101</volume><fpage>350</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18939721</pub-id></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CS</given-names></name><name><surname>Woolcock</surname><given-names>AJ</given-names></name><name><surname>Sullivan</surname><given-names>CE</given-names></name></person-group><article-title>Nocturnal asthma: role of snoring and obstructive sleep apnea</article-title><source>Am Rev Respir Dis</source><year>1988</year><volume>137</volume><fpage>1502</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">3059864</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atlantis</surname><given-names>E</given-names></name><name><surname>Sullivan</surname><given-names>T</given-names></name><name><surname>Sartorius</surname><given-names>N</given-names></name><name><surname>Almeida</surname><given-names>OP</given-names></name></person-group><article-title>Changes in the prevalence of psychological distress and use of antidepressants or anti-anxiety medications associated with comorbid chronic diseases in the adult Australian population, 2001&#x02013;2008</article-title><source>Aust N Z J Psychiatry</source><year>2012</year><volume>46</volume><fpage>445</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">22535293</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strine</surname><given-names>TW</given-names></name><name><surname>Mokdad</surname><given-names>AH</given-names></name><name><surname>Balluz</surname><given-names>LS</given-names></name><name><surname>Berry</surname><given-names>JT</given-names></name><name><surname>Gonzalez</surname><given-names>O</given-names></name></person-group><article-title>Impact of depression and anxiety on quality of life, health behaviors, and asthma control among adults in the United States with asthma, 2006</article-title><source>J Asthma</source><year>2008</year><volume>45</volume><fpage>123</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18350404</pub-id></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>HP</given-names></name><name><surname>Ji</surname><given-names>YL</given-names></name></person-group><article-title>Relationship between current psychological symptoms and future risk of asthma outcomes: a 12-month prospective cohort study</article-title><source>J Asthma</source><year>2011</year><volume>48</volume><fpage>1041</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">22091741</pub-id></element-citation></ref><ref id="CIT0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ten Brinke</surname><given-names>A</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Masclee</surname><given-names>AA</given-names></name><name><surname>Spinhoven</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>JT</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Risk factors of frequent exacerbations in difficult-to-treat asthma</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><fpage>812</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">16264041</pub-id></element-citation></ref><ref id="CIT0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Pujol</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Schiaffino</surname><given-names>A</given-names></name><name><surname>Moncada</surname><given-names>A</given-names></name><name><surname>Ariza</surname><given-names>C</given-names></name><name><surname>Blanch</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tobacco smoking, exposure to second-hand smoke, and asthma and wheezing in schoolchildren: a cross-sectional study</article-title><source>Acta Paediatr</source><year>2013</year><volume>102</volume><fpage>e305</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23581609</pub-id></element-citation></ref><ref id="CIT0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Yelin</surname><given-names>EH</given-names></name><name><surname>Trupin</surname><given-names>L</given-names></name><name><surname>Blanc</surname><given-names>PD</given-names></name></person-group><article-title>Asthma and smoking status in a population-based study of California adults</article-title><source>Public Health Rep</source><year>2001</year><volume>116</volume><fpage>148</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">11847300</pub-id></element-citation></ref><ref id="CIT0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietinalho</surname><given-names>A</given-names></name><name><surname>Pelkonen</surname><given-names>A</given-names></name><name><surname>Rytila</surname><given-names>P</given-names></name></person-group><article-title>Linkage between smoking and asthma</article-title><source>Allergy</source><year>2009</year><volume>64</volume><fpage>1722</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19832738</pub-id></element-citation></ref><ref id="CIT0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>NC</given-names></name><name><surname>Chaudhuri</surname><given-names>R</given-names></name><name><surname>Heaney</surname><given-names>LG</given-names></name><name><surname>Bucknall</surname><given-names>C</given-names></name><name><surname>Niven</surname><given-names>RM</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma</article-title><source>J Allergy Clin Immunol</source><year>2013</year><volume>131</volume><fpage>1008</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">23419540</pub-id></element-citation></ref><ref id="CIT0039"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarus</surname><given-names>SC</given-names></name><name><surname>Chinchilli</surname><given-names>VM</given-names></name><name><surname>Rollings</surname><given-names>NJ</given-names></name><name><surname>Boushey</surname><given-names>HA</given-names></name><name><surname>Cherniack</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>175</volume><fpage>783</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17204725</pub-id></element-citation></ref><ref id="CIT0040"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comhair</surname><given-names>SA</given-names></name><name><surname>Gaston</surname><given-names>BM</given-names></name><name><surname>Ricci</surname><given-names>KS</given-names></name><name><surname>Hammel</surname><given-names>J</given-names></name><name><surname>Dweik</surname><given-names>RA</given-names></name><name><surname>Teague</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Detrimental effects of environmental tobacco smoke in relation to asthma severity</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e18574</fpage><pub-id pub-id-type="pmid">21572527</pub-id></element-citation></ref><ref id="CIT0041"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>SE</given-names></name></person-group><article-title>Asthma phenotypes: the evolution from clinical to molecular approaches</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>716</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">22561835</pub-id></element-citation></ref><ref id="CIT0042"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>DeKruyff</surname><given-names>RH</given-names></name><name><surname>Umetsu</surname><given-names>DT</given-names></name></person-group><article-title>The many paths to asthma: phenotype shaped by innate and adaptive immunity</article-title><source>Nat Immunol</source><year>2010</year><volume>11</volume><fpage>577</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">20562844</pub-id></element-citation></ref><ref id="CIT0043"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkelman</surname><given-names>FD</given-names></name><name><surname>Katona</surname><given-names>IM</given-names></name><name><surname>Urban</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Ohara</surname><given-names>J</given-names></name><name><surname>Tung</surname><given-names>AS</given-names></name><etal/></person-group><article-title>IL-4 is required to generate and sustain in vivo IgE responses</article-title><source>J Immunol</source><year>1988</year><volume>141</volume><fpage>2335</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">2459206</pub-id></element-citation></ref><ref id="CIT0044"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Immunology of asthma and chronic obstructive pulmonary disease</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><fpage>183</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">18274560</pub-id></element-citation></ref><ref id="CIT0045"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>WC</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>Wenzel</surname><given-names>SE</given-names></name><name><surname>Teague</surname><given-names>WG</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>315</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19892860</pub-id></element-citation></ref><ref id="CIT0046"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallstrand</surname><given-names>TS</given-names></name><name><surname>Moody</surname><given-names>MW</given-names></name><name><surname>Aitken</surname><given-names>ML</given-names></name><name><surname>Henderson</surname><given-names>WR</given-names><suffix>Jr</suffix></name></person-group><article-title>Airway immunopathology of asthma with exercise-induced bronchoconstriction</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>116</volume><fpage>586</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16159628</pub-id></element-citation></ref><ref id="CIT0047"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haldar</surname><given-names>P</given-names></name><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Berry</surname><given-names>MA</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Cluster analysis and clinical asthma phenotypes</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>178</volume><fpage>218</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">18480428</pub-id></element-citation></ref><ref id="CIT0048"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>PG</given-names></name><name><surname>Modrek</surname><given-names>B</given-names></name><name><surname>Choy</surname><given-names>DF</given-names></name><name><surname>Jia</surname><given-names>G</given-names></name><name><surname>Abbas</surname><given-names>AR</given-names></name><name><surname>Ellwanger</surname><given-names>A</given-names></name><etal/></person-group><article-title>T-helper type 2-driven inflammation defines major subphenotypes of asthma</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>180</volume><fpage>388</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">19483109</pub-id></element-citation></ref><ref id="CIT0049"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>WW</given-names></name></person-group><article-title>Anti-immunoglobulin E (omalizumab) therapy in allergic asthma</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>S12</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11704612</pub-id></element-citation></ref><ref id="CIT0050"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimaldi-Bensouda</surname><given-names>L</given-names></name><name><surname>Zureik</surname><given-names>M</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>J</given-names></name><name><surname>Benichou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma</article-title><source>Chest</source><year>2013</year><volume>143</volume><fpage>398</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">23505637</pub-id></element-citation></ref><ref id="CIT0051"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holgate</surname><given-names>S</given-names></name><name><surname>Casale</surname><given-names>T</given-names></name><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Deniz</surname><given-names>Y</given-names></name><name><surname>Reisner</surname><given-names>C</given-names></name></person-group><article-title>The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>115</volume><fpage>459</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">15753888</pub-id></element-citation></ref><ref id="CIT0052"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>K</given-names></name><name><surname>Hsieh</surname><given-names>HJ</given-names></name><name><surname>Mosesova</surname><given-names>S</given-names></name><name><surname>Choy</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>187</volume><fpage>804</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">23471469</pub-id></element-citation></ref><ref id="CIT0053"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Llano</surname><given-names>LP</given-names></name><name><surname>Vennera Mdel</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>FJ</given-names></name><name><surname>Medina</surname><given-names>JF</given-names></name><name><surname>Borderias</surname><given-names>L</given-names></name><name><surname>Pellicer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry</article-title><source>J Asthma</source><year>2013</year><volume>50</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">23350994</pub-id></element-citation></ref><ref id="CIT0054"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>G</given-names></name><name><surname>Magnan</surname><given-names>A</given-names></name><name><surname>Chiron</surname><given-names>R</given-names></name><name><surname>Contin-Bordes</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Taille</surname><given-names>C</given-names></name><etal/></person-group><article-title>A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma</article-title><source>Chest</source><year>2013</year><volume>144</volume><fpage>411</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23579324</pub-id></element-citation></ref><ref id="CIT0055"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightbill</surname><given-names>HD</given-names></name><name><surname>Jeet</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><fpage>2218</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">20458139</pub-id></element-citation></ref><ref id="CIT0056"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flood-Page</surname><given-names>P</given-names></name><name><surname>Swenson</surname><given-names>C</given-names></name><name><surname>Faiferman</surname><given-names>I</given-names></name><name><surname>Matthews</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Brannick</surname><given-names>L</given-names></name><etal/></person-group><article-title>A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><fpage>1062</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17872493</pub-id></element-citation></ref><ref id="CIT0057"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kips</surname><given-names>JC</given-names></name><name><surname>O'Connor</surname><given-names>BJ</given-names></name><name><surname>Langley</surname><given-names>SJ</given-names></name><name><surname>Woodcock</surname><given-names>A</given-names></name><name><surname>Kerstjens</surname><given-names>HA</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>1655</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12649124</pub-id></element-citation></ref><ref id="CIT0058"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><name><surname>Howarth</surname><given-names>P</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Keene</surname><given-names>ON</given-names></name><etal/></person-group><article-title>Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>651</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22901886</pub-id></element-citation></ref><ref id="CIT0059"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laviolette</surname><given-names>M</given-names></name><name><surname>Gossage</surname><given-names>DL</given-names></name><name><surname>Gauvreau</surname><given-names>G</given-names></name><name><surname>Leigh</surname><given-names>R</given-names></name><name><surname>Olivenstein</surname><given-names>R</given-names></name><name><surname>Katial</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia</article-title><source>J Allergy Clin Immunol</source><year>2013</year><volume>132</volume><fpage>1086</fpage><lpage>96.e5</lpage><pub-id pub-id-type="pmid">23866823</pub-id></element-citation></ref><ref id="CIT0060"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>SE</given-names></name><name><surname>Balzar</surname><given-names>S</given-names></name><name><surname>Ampleford</surname><given-names>E</given-names></name><name><surname>Hawkins</surname><given-names>GA</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Calhoun</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>175</volume><fpage>570</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17170387</pub-id></element-citation></ref><ref id="CIT0061"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Wilbraham</surname><given-names>D</given-names></name><name><surname>Fuller</surname><given-names>R</given-names></name><name><surname>Getz</surname><given-names>EB</given-names></name><name><surname>Longphre</surname><given-names>M</given-names></name></person-group><article-title>Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>1422</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17950857</pub-id></element-citation></ref><ref id="CIT0062"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Ford</surname><given-names>L</given-names></name><name><surname>Pearlman</surname><given-names>D</given-names></name><name><surname>Spector</surname><given-names>S</given-names></name><name><surname>Sher</surname><given-names>L</given-names></name><name><surname>Skobieranda</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dupilumab in persistent asthma with elevated eosinophil levels</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>2455</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">23688323</pub-id></element-citation></ref><ref id="CIT0063"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corren</surname><given-names>J</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names></name><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Korenblat</surname><given-names>PE</given-names></name><name><surname>Parsey</surname><given-names>MV</given-names></name><name><surname>Arron</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Lebrikizumab treatment in adults with asthma</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>1088</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">21812663</pub-id></element-citation></ref><ref id="CIT0064"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schleich</surname><given-names>FN</given-names></name><name><surname>Manise</surname><given-names>M</given-names></name><name><surname>Sele</surname><given-names>J</given-names></name><name><surname>Henket</surname><given-names>M</given-names></name><name><surname>Seidel</surname><given-names>L</given-names></name><name><surname>Louis</surname><given-names>R</given-names></name></person-group><article-title>Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation</article-title><source>BMC Pulm Med</source><year>2013</year><volume>13</volume><fpage>11</fpage><pub-id pub-id-type="pmid">23442497</pub-id></element-citation></ref><ref id="CIT0065"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullens</surname><given-names>DM</given-names></name><name><surname>Truyen</surname><given-names>E</given-names></name><name><surname>Coteur</surname><given-names>L</given-names></name><name><surname>Dilissen</surname><given-names>E</given-names></name><name><surname>Hellings</surname><given-names>PW</given-names></name><name><surname>Dupont</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?</article-title><source>Respir Res</source><year>2006</year><volume>7</volume><fpage>135</fpage><pub-id pub-id-type="pmid">17083726</pub-id></element-citation></ref><ref id="CIT0066"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molet</surname><given-names>S</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Davoine</surname><given-names>F</given-names></name><name><surname>Nutku</surname><given-names>E</given-names></name><name><surname>Taha</surname><given-names>R</given-names></name><name><surname>Page</surname><given-names>N</given-names></name><etal/></person-group><article-title>IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>108</volume><fpage>430</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11544464</pub-id></element-citation></ref><ref id="CIT0067"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Ho</surname><given-names>CY</given-names></name><name><surname>Ko</surname><given-names>FW</given-names></name><name><surname>Chan</surname><given-names>CH</given-names></name><name><surname>Ho</surname><given-names>AS</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma</article-title><source>Clin Exp Immunol</source><year>2001</year><volume>125</volume><fpage>177</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11529906</pub-id></element-citation></ref><ref id="CIT0068"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinley</surname><given-names>L</given-names></name><name><surname>Alcorn</surname><given-names>JF</given-names></name><name><surname>Peterson</surname><given-names>A</given-names></name><name><surname>Dupont</surname><given-names>RB</given-names></name><name><surname>Kapadia</surname><given-names>S</given-names></name><name><surname>Logar</surname><given-names>A</given-names></name><etal/></person-group><article-title>TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice</article-title><source>J Immunol</source><year>2008</year><volume>181</volume><fpage>4089</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">18768865</pub-id></element-citation></ref><ref id="CIT0069"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogil</surname><given-names>J</given-names></name></person-group><article-title>Many asthma patients experience persistent symptoms despite appropriate clinical and guideline-based treatment with inhaled corticosteroids</article-title><source>J Am Acad Nurse Pract</source><year>2007</year><volume>19</volume><fpage>459</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17760570</pub-id></element-citation></ref><ref id="CIT0070"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adcock</surname><given-names>IM</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Molecular mechanisms of corticosteroid resistance</article-title><source>Chest</source><year>2008</year><volume>134</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">18682458</pub-id></element-citation></ref><ref id="CIT0071"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhavsar</surname><given-names>P</given-names></name><name><surname>Hew</surname><given-names>M</given-names></name><name><surname>Khorasani</surname><given-names>N</given-names></name><name><surname>Torrego</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Adcock</surname><given-names>I</given-names></name><etal/></person-group><article-title>Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma</article-title><source>Thorax</source><year>2008</year><volume>63</volume><fpage>784</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18492738</pub-id></element-citation></ref><ref id="CIT0072"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez-Tello</surname><given-names>A</given-names></name><name><surname>Semlali</surname><given-names>A</given-names></name><name><surname>Chakir</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JG</given-names></name><name><surname>Leung</surname><given-names>DY</given-names></name><name><surname>Eidelman</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines</article-title><source>Clin Exp Allergy</source><year>2010</year><volume>40</volume><fpage>1312</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20545708</pub-id></element-citation></ref><ref id="CIT0073"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Adcock</surname><given-names>IM</given-names></name></person-group><article-title>Glucocorticoid resistance in inflammatory diseases</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1905</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">19482216</pub-id></element-citation></ref><ref id="CIT0074"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howarth</surname><given-names>PH</given-names></name><name><surname>Babu</surname><given-names>KS</given-names></name><name><surname>Arshad</surname><given-names>HS</given-names></name><name><surname>Lau</surname><given-names>L</given-names></name><name><surname>Buckley</surname><given-names>M</given-names></name><name><surname>McConnell</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma</article-title><source>Thorax</source><year>2005</year><volume>60</volume><fpage>1012</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16166100</pub-id></element-citation></ref><ref id="CIT0075"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MA</given-names></name><name><surname>Hargadon</surname><given-names>B</given-names></name><name><surname>Shelley</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Green</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Evidence of a role of tumor necrosis factor alpha in refractory asthma</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">16481637</pub-id></element-citation></ref><ref id="CIT0076"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erin</surname><given-names>EM</given-names></name><name><surname>Leaker</surname><given-names>BR</given-names></name><name><surname>Nicholson</surname><given-names>GC</given-names></name><name><surname>Tan</surname><given-names>AJ</given-names></name><name><surname>Green</surname><given-names>LM</given-names></name><name><surname>Neighbour</surname><given-names>H</given-names></name><etal/></person-group><article-title>The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>753</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16840747</pub-id></element-citation></ref><ref id="CIT0077"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>SE</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Busse</surname><given-names>W</given-names></name><name><surname>Dahlen</surname><given-names>SE</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><fpage>549</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">19136369</pub-id></element-citation></ref><ref id="CIT0078"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Holgate</surname><given-names>S</given-names></name><name><surname>Kerwin</surname><given-names>E</given-names></name><name><surname>Chon</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>188</volume><fpage>1294</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">24200404</pub-id></element-citation></ref><ref id="CIT0079"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>JM</given-names></name><name><surname>Oh</surname><given-names>CK</given-names></name><name><surname>LaForce</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name><name><surname>Pearlman</surname><given-names>DS</given-names></name><name><surname>Le</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma</article-title><source>BMC Pulm Med</source><year>2011</year><volume>11</volume><fpage>14</fpage><pub-id pub-id-type="pmid">21356110</pub-id></element-citation></ref><ref id="CIT0080"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>MJ</given-names></name></person-group><article-title>Therapy directed against thymic stromal lymphopoietin</article-title><source>Drug News Perspect</source><year>2008</year><volume>21</volume><fpage>312</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">18836588</pub-id></element-citation></ref><ref id="CIT0081"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catley</surname><given-names>MC</given-names></name><name><surname>Coote</surname><given-names>J</given-names></name><name><surname>Bari</surname><given-names>M</given-names></name><name><surname>Tomlinson</surname><given-names>KL</given-names></name></person-group><article-title>Monoclonal antibodies for the treatment of asthma</article-title><source>Pharmacol Ther</source><year>2011</year><volume>132</volume><fpage>333</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21944943</pub-id></element-citation></ref><ref id="CIT0082"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>New therapies for asthma: is there any progress?</article-title><source>Trends Pharmacol Sci</source><year>2010</year><volume>31</volume><fpage>335</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">20554041</pub-id></element-citation></ref><ref id="CIT0083"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>GP</given-names></name></person-group><article-title>Prospects for an asthma vaccine</article-title><source>Respirology</source><year>2010</year><volume>15</volume><fpage>902</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20663094</pub-id></element-citation></ref><ref id="CIT0084"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>PN</given-names></name><name><surname>Scragg</surname><given-names>R</given-names></name></person-group><article-title>Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third National Health and Nutrition Examination Survey</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>3792</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16354847</pub-id></element-citation></ref><ref id="CIT0085"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannell</surname><given-names>JJ</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name><name><surname>Umhau</surname><given-names>JC</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Grant</surname><given-names>WB</given-names></name><name><surname>Madronich</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epidemic influenza and vitamin D</article-title><source>Epidemiol Infect</source><year>2006</year><volume>134</volume><fpage>1129</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16959053</pub-id></element-citation></ref><ref id="CIT0086"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloia</surname><given-names>JF</given-names></name><name><surname>Li-Ng</surname><given-names>M</given-names></name></person-group><article-title>Re: epidemic influenza and vitamin D</article-title><source>Epidemiol Infect</source><year>2007</year><volume>135</volume><fpage>1095</fpage><lpage>6</lpage><comment>author reply 1097&#x02013;8</comment><pub-id pub-id-type="pmid">17352842</pub-id></element-citation></ref><ref id="CIT0087"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bener</surname><given-names>A</given-names></name><name><surname>Ehlayel</surname><given-names>MS</given-names></name><name><surname>Tulic</surname><given-names>MK</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name></person-group><article-title>Vitamin D deficiency as a strong predictor of asthma in children</article-title><source>Int Arch Allergy Immunol</source><year>2012</year><volume>157</volume><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">21986034</pub-id></element-citation></ref><ref id="CIT0088"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>G</given-names></name><name><surname>Brehm</surname><given-names>J</given-names></name><name><surname>Alcorn</surname><given-names>JF</given-names></name><name><surname>Holguin</surname><given-names>F</given-names></name><name><surname>Aujla</surname><given-names>S</given-names></name><name><surname>Celedon</surname><given-names>JC</given-names></name></person-group><article-title>Vitamin D and asthma</article-title><source>Am J Respir Crit Care Med</source><year>2012</year><volume>185</volume><fpage>124</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">22016447</pub-id></element-citation></ref><ref id="CIT0089"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brehm</surname><given-names>JM</given-names></name><name><surname>Celedon</surname><given-names>JC</given-names></name><name><surname>Soto-Quiros</surname><given-names>ME</given-names></name><name><surname>Avila</surname><given-names>L</given-names></name><name><surname>Hunninghake</surname><given-names>GM</given-names></name><name><surname>Forno</surname><given-names>E</given-names></name><etal/></person-group><article-title>Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><fpage>765</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">19179486</pub-id></element-citation></ref><ref id="CIT0090"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Sjoukes</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>D</given-names></name><name><surname>Banya</surname><given-names>W</given-names></name><name><surname>Hawrylowicz</surname><given-names>C</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma</article-title><source>Am J Respir Crit Care Med</source><year>2011</year><volume>184</volume><fpage>1342</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21908411</pub-id></element-citation></ref><ref id="CIT0091"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanzer</surname><given-names>AM</given-names></name><name><surname>Chambers</surname><given-names>ES</given-names></name><name><surname>Ryanna</surname><given-names>K</given-names></name><name><surname>Richards</surname><given-names>DF</given-names></name><name><surname>Black</surname><given-names>C</given-names></name><name><surname>Timms</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Enhanced production of IL-17A in patients with severe asthma is inhibited by 1alpha,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion</article-title><source>J Allergy Clin Immunol</source><year>2013</year><volume>132</volume><fpage>297</fpage><lpage>304.e3</lpage><pub-id pub-id-type="pmid">23683514</pub-id></element-citation></ref><ref id="CIT0092"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>Vanderstichele</surname><given-names>C</given-names></name><name><surname>Jordens</surname><given-names>P</given-names></name><name><surname>Deman</surname><given-names>R</given-names></name><name><surname>Slabbynck</surname><given-names>H</given-names></name><name><surname>Ringoet</surname><given-names>V</given-names></name><etal/></person-group><article-title>Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial</article-title><source>Thorax</source><year>2013</year><volume>68</volume><fpage>322</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23291349</pub-id></element-citation></ref><ref id="CIT0093"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Olson</surname><given-names>L</given-names></name><name><surname>Gibson</surname><given-names>P</given-names></name></person-group><article-title>Methotrexate as a steroid sparing agent for asthma in adults</article-title><source>Cochrane Database Syst Rev</source><year>2000</year><fpage>CD000391</fpage><pub-id pub-id-type="pmid">10796540</pub-id></element-citation></ref><ref id="CIT0094"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>AS</given-names></name><name><surname>Laviolette</surname><given-names>M</given-names></name><name><surname>Fiterman</surname><given-names>J</given-names></name><name><surname>De Andrade Lima</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>116</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19815809</pub-id></element-citation></ref><ref id="CIT0095"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>ME</given-names></name><name><surname>Laviolette</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>AS</given-names></name><name><surname>Fiterman</surname><given-names>J</given-names></name><name><surname>Lapa e Silva</surname><given-names>JR</given-names></name><name><surname>Shah</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma</article-title><source>J Allergy Clin Immunol</source><year>2013</year><volume>132</volume><fpage>1295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">23998657</pub-id></element-citation></ref></ref-list></back></article>